1. Home
  2. HZO vs GLUE Comparison

HZO vs GLUE Comparison

Compare HZO & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MarineMax Inc.  (FL)

HZO

MarineMax Inc. (FL)

SELL

Current Price

$52.45

Market Cap

1.2B

ML Signal

SELL

Logo Monte Rosa Therapeutics Inc.

GLUE

Monte Rosa Therapeutics Inc.

HOLD

Current Price

$10.75

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HZO
GLUE
Founded
1998
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Auto & Home Supply Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.2B
IPO Year
1998
2021

Fundamental Metrics

Financial Performance
Metric
HZO
GLUE
Price
$52.45
$10.75
Analyst Decision
Hold
Strong Buy
Analyst Count
9
10
Target Price
★ $49.40
$26.88
AVG Volume (30 Days)
692.1K
★ 1.3M
Earning Date
11-12-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ 0.21
N/A
Revenue
★ $2,309,288,000.00
$123,672,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$4.38
N/A
P/E Ratio
$250.60
★ $72.42
Revenue Growth
N/A
★ 63.54
52 Week Low
$21.42
$9.68
52 Week High
$52.65
$25.77

Technical Indicators

Market Signals
Indicator
HZO
GLUE
Relative Strength Index (RSI) 60.56 43.86
Support Level $52.16 $9.69
Resistance Level $52.45 $12.26
Average True Range (ATR) 0.15 0.59
MACD -0.11 0.26
Stochastic Oscillator 72.22 53.64

Price Performance

Historical Comparison
HZO
GLUE

About HZO MarineMax Inc. (FL)

MarineMax Inc is a United-States-based company that sells new and used recreational boats under premium brands, and related marine products, like engines, parts, and accessories. The company is also engaged in other businesses, including providing services of repair, maintenance, and storage; managing related boat financing, insurance, and others; offering brokerage sales of boats and yachts; and operating a yacht charter business. The reportable segments of the company are Retail Operations and Product Manufacturing. The Retail Operations segment generates the majority of the company's revenue. The sale of new and used boats accounts for the majority of the company's total revenue. It serves customers across the U.S and international market.

About GLUE Monte Rosa Therapeutics Inc.

Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).

Share on Social Networks: